NEW YORK (TheStreet) - The death Wednesday of the first Ebola patient in the U.S. sent shares of Chimerix (CMRX) - Get Report , the maker of the treatment that of Thomas Eric Duncan was on, plunging more than 9%.

The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.

The virus has killed more than 3,400 people in West Africa and has now spread to other countries besides the U.S. The Center for Disease Control is forecasting 1.4 million cases by late January if nothing changes.

Here are 10 companies that are trying to play a role in curbing the outbreak.

Image placeholder title


Chimerix's (CMRX) - Get Report shares had jumped 39% over the past month, but the stock was tanking following the news of Duncan's death.

The company's brincidofovir, an oral antiviral drug, was reportedly being used to treat Duncan, who contracted the disease while in Liberia. Brincidofovir was also used to treat the freelance cameraman who contracted Ebola while on assignment, according to Forbes.

Image placeholder title

2. Tekmira Pharmaceuticals

Shares of Tekmira Pharmaceuticals (TKMR) have risen 20.6% over the past month. This stock was also trading 1.8% lower on Wednesday.

The Vancouver-based company said in August that its TKM-Ebola Investigation New Drug Application was modified from "full clinical hold" to "partial clinical hold." The action enabled the use of TKM-Ebola in individuals infected with Ebola virus.

In early September, Dr. Rick Sacra, the U.S. doctor who contracted Ebola while treating patients in West Africa, received TKM-Ebola in addition to serum from the blood of another cured Ebola patient, among other therapies.

Image placeholder title

3. Sarepta Therapeutics

Sarepta Therapeutics (SRPT) - Get Reportshares are down 13.5% over the last month. The company has urged the government to use its experimental treatment for the virus. The company said in August it had enough doses of its "injectible drug - AVI-7537 - to treat about two dozen patients within a week and could ramp up a supply for another 100 patients within a few months," according to an Aug. 6 article from The Boston Globe.

Image placeholder title

4. BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (BCRX) - Get Report shares are down 7.6% over the last month. It was one of several vaccine-developing companies asked by the World Health Organization to provide summaries of potential Ebola vaccines. BioCryst's antiviral BCX4430 is a drug candidate for the treatment of Ebola and other hemorrhagic fever virus diseases, the Research Triangle Park, N.C.-based company said in a September release.

Image placeholder title

5. NewLink Genetics

NewLink Genetics (NLNK) - Get Report shares are down 26.5% over the past month. The Ames, Iowa-based biopharmaceutical company is working on an Ebola vaccine, despite being primarily focused cancer-related treatments.

The company says on its Web site that it was "expanding its pipeline to address infectious diseases caused by the influenza and Ebola virus to enable us to maximize the application of HyperAcute immunotherapies to potentially transform the lives of patients with other serious and life-threatening diseases."

NewLink's CFO Gordon Link told The Des Moines Register in August that the company was "fast-tracking" its Ebola vaccine.

Image placeholder title

6. Hemispherx Biopharma

Hemispherx Biopharma (HEB) shares are down less than 1% over the past month, but the penny stock jumped 23% last week following its Sept. 29 announcement that it "widened set of research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation."

Image placeholder title

7. Inovio Pharmaceuticals

Shares of Inovio Pharmaceuticals (INO) - Get Report are down 3.2% over the past month. The company said on Sept. 24 that it plans to advance its Ebola vaccine into a phase I clinical trials in collaboration with GeneOne Life Science, an international DNA vaccine manufacturer in which Inovio holds a minority interest.

"There are no proven agents to check the spread of Ebola, which is now becoming a health threat of global concern," Inovio CEO Dr. J. Joseph Kim said in the press release. "We are therefore taking the steps with our collaborator to establish the safety and immunogenicity of our Ebola vaccine in humans and be in a position to further advance these agents to help fight this challenging disease."

Image placeholder title

8. NanoViricides

NanoViricides (NNVC) - Get Report shares are down 9.7% over the past month. The West Haven, Conn.-based company said in early August that it was restarting its drug development program to combat Ebola virus infections.

Image placeholder title

9. Lakeland Industries

Hazmat suit maker Lakeland Industries (LAKE) - Get Report shares are up 59% over the past month. The Ronkonkoma, N.Y.-based company said in September that it was boosting production of its protective apparel for use in handling the Ebola virus.

"In response to the increasing demand for specialty protective suits to be worn by healthcare workers and others being exposed to Ebola, Lakeland is increasing its manufacturing capacity for these garments and includes proprietary processes for specialized seam sealing, a far superior technology for protecting against viral hazards than non-sealed products," the company said in a Sept. 12 release.

Image placeholder title

10. GlaxoSmithKline

GlaxoSmithKline (GSK) - Get Report shares are down 3.4% over the past month, despite the fact that the World Health Organization is clamoring for solutions to the Ebola outbreak and asking the U.K. company top "fast track" its Ebola vaccine.

The company said in late August that human trials of its vaccine, being co-developed by the U.S.National Institutes of Health (NIH), "are to be accelerated with funding from an international consortium in response to the Ebola epidemic."

However, despite GlaxoSmithKline ramping up production, its chairman of research told CNBC on Tuesday that it "does not expect to be able to make it in mass quantities for 12 to 18 months."

-Written by Laurie Kulikowski in New York.

Follow @LKulikowski

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.